Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 14 November 2025 - 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) secured a sustainable supply of pharmaceutical-grade ibogaine through PsyLabs, receiving an initial 50 kg shipment of high-potency iboga bark for processing. PBM shares rose 21.5% to $3.39 in pre-market trading Thursday, after being named among top healthcare movers.
20 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk’s U.S. ADR traded near $49 Thursday, steady after a 3% rebound, while Copenhagen shares rose about 2–2.5% to DKK 318–319. The company faces slowing GLP-1 demand, price cuts, and high-profile Alzheimer’s trials, with results expected December 3. Shares remain down over 10% in three months and nearly 46% year-to-date after guidance cuts.
20 November 2025
···
Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals’ Phase 3 RISE UP trial of mitapivat in sickle cell disease met its hemoglobin-response primary endpoint but failed to show a significant reduction in pain crises or fatigue. Shares fell sharply, dropping as much as 50% pre-market before paring losses. The company plans to meet with the FDA in early 2026 to discuss a potential U.S. marketing application.
19 November 2025
··
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

Kenvue shares traded near $16.13 midday, down 0.7%, after a U.S. appeals court signaled it may revive over 500 Tylenol-autism lawsuits. A Texas judge declined to block Kenvue’s $398 million dividend, which remains set for Nov. 26. The pending Kimberly-Clark deal implies $18.83 per share for KVUE, about 14% above its current price. Volume reached 21.1 million shares by 17:32 UTC.
18 November 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Novo Nordisk cut U.S. self-pay prices for Wegovy and Ozempic and launched a $199 two-month introductory offer for new patients. Shares fell 1.9% to $47.55 intraday as investors weighed pricing pressure and governance changes. Novo Holdings exited its 7.8% stake in ConvaTec in London. Trading volumes reached about 7.9 million shares by 16:12 UTC.
18 November 2025
··
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

Merck shares rose about 3%–4% Tuesday after the company said its drug Winrevair met the main goal in a Phase 2 study for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction. Merck plans to advance the drug to Phase 3 trials. The update follows last week’s $9.2 billion deal to acquire Cidara Therapeutics.
18 November 2025
··
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····
Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer (PFE) Stock Today, November 17, 2025: Migraine Drug Launch in India, Metsera Deal Closes and New RSV Vaccine Data

Pfizer launched Rimegepant ODT, a migraine tablet, in India, targeting a $200 million market. Shares traded near $25.28, down 55% from late 2022, with a dividend yield around 7%. Analysts maintain a “Hold” rating and see limited short-term movement. The new product addresses migraine in adults unresponsive to standard treatments.
17 November 2025
··
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals said its fibromyalgia drug TONMYA is now available by prescription across the U.S. Shares of Tonix (NASDAQ: TNXP) rose nearly 8% in early trading, reaching $17.16. TONMYA, approved by the FDA in August 2025, is the first new fibromyalgia therapy in over 15 years. The company reported the launch in a Form 8-K filing with the SEC.
17 November 2025
··
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals reported that a triple-drug combination of Aramchol, Stivarga, and metformin sharply increased tumor cell killing in GI cancer models. Shares jumped as much as 38.6% premarket and traded around $1.18 by afternoon, with volume exceeding 41 million shares. The company plans a Phase 1b trial at VCU Massey Comprehensive Cancer Center in early 2026. New U.S. patent applications have been filed for the combination.
17 November 2025
···
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash, expanding its oncology portfolio. Halda’s lead drug candidate targets advanced prostate cancer. The deal is expected to close in the coming months, pending regulatory approval. J&J faces declining Stelara sales as biosimilar competition increases.
17 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Eli Lilly shares traded near $1,025 on Nov. 15, valuing the company just under $1 trillion. The White House announced a deal to lower Zepbound prices and expand public access, while Lilly expects FDA approval of its oral GLP‑1 pill by March 2026. Q3 revenue rose 54% to $17.6 billion. Lilly Endowment filed stock sales around the $1,000 level this month.
15 November 2025
·
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson have halted the Phase 3 Librexia ACS trial of milvexian in acute coronary syndrome after an interim review showed the drug was unlikely to meet its main efficacy goal. BMY shares fell following the announcement. No new safety issues were reported. The trial had aimed to enroll about 16,000 patients worldwide.
14 November 2025
···
1 … 31 32 33 34 35 … 38

Stock Market Today

  • Cocoa Prices Rise as Dollar Weakness Triggers Short Covering Amid Supply, Demand Concerns
    April 11, 2026, 3:25 AM EDT. Cocoa prices surged with May ICE NY cocoa up 2.66% and London cocoa gaining 2.37%, driven by short covering after dollar weakness. London fund shorts hit an 8-year high, adding fuel to the rally. Despite increased shipments from Ivory Coast and record ICE inventories signaling ample supply, drought in West Africa and fertilizer cost rises from Strait of Hormuz closure support prices. Demand remains weak; Easter chocolate sales estimate a 5% drop, with Barry Callebaut reporting a 22% sales volume decline. European cocoa grindings fell 8.3% year-on-year in Q4, exceeding expectations, reflecting ongoing consumption challenges amid high chocolate prices.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 3:35 AM EDT Cocoa Prices Rise as Dollar Weakness Triggers Short Covering Amid Supply, Demand Concerns April 11, 2026, 3:25 AM EDT. Cocoa prices surged with May ICE NY cocoa up 2.66% and London cocoa gaining 2.37%, driven by short covering after dollar weakness. London fund shorts hit an 8-year high, adding fuel to the rally. Despite increased shipments from Ivory Coast and record ICE inventories signaling ample supply, drought in West Africa and fertilizer cost rises from Strait of Hormuz closure support prices. Demand remains weak; Easter
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop